Keros Therapeutics (KROS) EPS (Basic) (2019 - 2026)
Keros Therapeutics' (KROS) quarterly EPS (Basic) came in at -$1.45 in Q2 2026, down 91.84% on a YoY basis from -$17.77 in Q2 2025, and down 130.04% quarter-over-quarter from -$0.63 in Q4 2025.
Powered by 
Analysis
Keros Therapeutics (KROS) EPS (Basic) (2019 - 2026) Analysis & Trends
Keros Therapeutics (KROS) has reported EPS (Basic) for 8 consecutive years, with -$1.45 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, EPS (Basic) fell 91.84% year-over-year to -$1.45; the trailing twelve-month figure through Jun 2026 stood at -$4.55 (down 1084.94% YoY), and the FY2025 full-year result was $2.34, up 146.71% from the prior year.
- EPS (Basic) eased to -$1.45 in Q2 2026 per KROS's latest filing, from -$0.63 in the prior quarter.
- Across five years, EPS (Basic) topped out at $3.66 in Q1 2025 and bottomed at -$1.45 in Q2 2026.
- Historically, EPS (Basic) has averaged -$0.82 across 5 years, with a median of -$1.21 in 2024.
- The sharpest annual moves came in 2022 and 2025: EPS (Basic) slumped 295.86% in 2022, then jumped 402.95% in 2025.
- Over 5 years, EPS (Basic) stood at -$1.18 in 2022, then decreased by 16.07% to -$1.37 in 2023, then increased by 10.04% to -$1.23 in 2024, then soared by 48.73% to -$0.63 in 2025, then tumbled by 130.04% to -$1.45 in 2026.
- According to Business Quant data, EPS (Basic) over the past three periods registered -$1.45, -$0.63, and -$0.18 for Q2 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.46 Bn | 192.47 Bn | 7.24 Bn | 4.40 |
| 2 | Gilead Sciences | 179.92 Bn | 176.75 Bn | 6.22 Bn | -8.44 |
| 3 | Vertex Pharmaceuticals | 131.37 Bn | 123.51 Bn | 2.84 Bn | 4.34 |
| 4 | Regeneron Pharmaceuticals | 81.86 Bn | 73.87 Bn | 3.93 Bn | 12.62 |
| 5 | Argenx Se | 60.29 Bn | 55.10 Bn | 1.37 Bn | 7.70 |
| 6 | Moderna | 53.76 Bn | 48.62 Bn | 52.00 Mn | -1.96 |
| 7 | Alnylam Pharmaceuticals | 33.16 Bn | 29.85 Bn | 992.69 Mn | 1.23 |
| 8 | Biogen | 31.90 Bn | 30.62 Bn | 1.96 Bn | 0.66 |
| 9 | Roivant Sciences | 29.13 Bn | 29.13 Bn | 1.16 Mn | -0.40 |
| 10 | Keros Therapeutics | 219.98 Mn | -37.62 Mn | - | -1.45 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1.45 |
| Dec 31, 2025 | -0.63 |
| Sep 30, 2025 | -0.18 |
| Jun 30, 2025 | -0.76 |
| Mar 31, 2025 | 3.66 |
| Dec 31, 2024 | -1.23 |
| Sep 30, 2024 | -1.41 |
| Jun 30, 2024 | -1.25 |
| Mar 31, 2024 | -1.21 |
| Dec 31, 2023 | -1.37 |
| Sep 30, 2023 | -1.33 |
| Jun 30, 2023 | -1.27 |
| Mar 31, 2023 | -1.26 |
| Dec 31, 2022 | -1.18 |
| Sep 30, 2022 | -0.92 |
| Jun 30, 2022 | -1.13 |
| Mar 31, 2022 | -1.01 |
| Dec 31, 2021 | -0.30 |
| Sep 30, 2021 | -0.87 |
| Jun 30, 2021 | -0.67 |